Five things for pharma marketers to know: Thursday, January 18, 2018
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
Breakthrough Therapy Designation
Five things for pharma marketers to know: Thursday, January 4, 2018
Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
Five things for pharma marketers to know: Monday, July 31, 2017
FDA launches digital health pre-certification pilot; J&J’s experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Five things for pharma marketers to know: Wednesday, June 7, 2017
Pfizer receives breakthrough designation for experimental rare disease drug; Endocyte cuts 30 jobs; AbbVie RA drug meets Phase-III goals
Five things for pharma marketers to know: Tuesday, April 18, 2017
Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals
Roche sclerosis drug granted Breakthrough Therapy status
Roche’s Actemra is already approved for three forms of arthritis.
Study: 10 medications will cost US $50 billion over 10 years
An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.
FDA grants Breakthrough status to Niemann-Pick drug
Genzyme’s experimental enzyme-replacement therapy olipudase alfa is being investigated for the Type B form of the condition.
AbbVie leukemia drug gets breakthrough status
AbbVie expected to submit chronic lymphocytic leukemia drug venetoclax to the FDA this year.
FDA grants Pfizer lung-cancer drug Breakthrough Designation
Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.
